CervoMed Inc. — Director's Dealing 2022

Aug 26, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Diffusion Pharmaceuticals Inc. (DFFN)
CIK: 0001053691
Period of Report: 2022-06-07

Reporting Person: JAEGER RAVEN (Chief Regulatory Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-07	Stock Option (Right to Buy)	$7.75	A	8000	Acquired	2032-06-07	Common Stock (8000)	Direct

Footnotes

F1: The shares underlying the options will vest in 36 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 36-month period beginning June 30, 2022.